The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
Cancer Communications2021Vol. 41(1), pp. 62–78
Citations Over TimeTop 10% of 2021 papers
Zongcai Liu, Fen Ning, Yanna Cai, Huiying Sheng, Ruidan Zheng, Xi Yin, Zhikun Lu, Ling Su, Xiaodan Chen, Chunhua Zeng, Haifang Wang, Li Liu
Abstract
The EGFR-P38 MAPK axis could up-regulate PD-L1 through miR-675-5p and down-regulate HLA-ABC via HK2 in HCC cells. Our study reveals a novel signaling network that may cause immune suppression in HCC and suggests that EGFR signaling can be targeted for HCC immunotherapy.
Related Papers
- → Application of comparative functional genomics to identify best-fit mouse models to study human cancer(2004)477 cited
- Mutations and aberrant transcriptions of Stk11 (Lkb1) gene in rat liver tumors.(2011)
- Expression of PCAN and RAR-α in hepatocellular carcinoma(2002)
- Pathologic Biomarkers that Indicate the Aggressiveness and Prognosis of Hepatocellular Carcinoma(2020)
- → Pan-Cancer Analysis of the Prognostic and Immunological Role of HCCS: A Potential Target for Survival and Immunotherapy(2023)